Lercapin

Lercanidipine, the active ingredient in Lercapin, is a calcium channel blocker presented as a tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercapin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercapin is a dihydropyridine calcium‑channel blocker used to manage elevated blood pressure. - Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. - Secondary hypertension: helps control blood pressure when it is caused by an underlying condition. - Hypertensive emergencies (under specialist supervision): may be incorporated into a regimen to lower dangerously high blood pressure.

Lercapin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: especially when standing quickly. - Tachycardia: increased heart rate. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat. - Elevated liver enzymes: indication of hepatic stress. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac conduction disturbances: such as heart block.

Before initiating therapy with Lercapin, certain safety considerations are recommended. - Monitor blood pressure: check regularly after starting treatment. - Assess cardiovascular status: use caution in patients with heart failure. - Evaluate renal function: adjust use if severe impairment is present. - Review concomitant medications: avoid known major interactions. - Pregnancy and lactation: prescribe only if clearly needed after risk assessment. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercapin can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - CYP3A4 inhibitors: may increase plasma concentrations of lercanidipine. - Strong CYP3A4 inducers: may reduce therapeutic effect. - Other antihypertensives: risk of excessive hypotension. - Grapefruit juice: can raise drug levels. - Lithium: may elevate lithium concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - Diuretics: may enhance antihypertensive response. - Antiplatelet agents: monitor for increased bleeding risk. - NSAIDs: can blunt antihypertensive efficacy. - Alcohol: may increase dizziness and hypotension.